NDAINTRAVENOUSSOLUTION
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (epinephrine) by Baxter International is (α)- and beta (β)-adrenergic receptors. First approved in 2025.
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Epinephrine bitartrate in 0.9% sodium chloride is an intravenous solution containing epinephrine, a non-selective adrenergic agonist that stimulates both α and β receptors. It is indicated for acute hemodynamic support in critical care settings, increasing cardiac contractility, heart rate, and peripheral vascular resistance. The drug works through direct myocardial stimulation (positive inotropic effect), increased heart rate (positive chronotropic effect), and peripheral vasoconstriction to rapidly restore blood pressure.
Growth
Recently approved product in growth phase with moderate competitive pressure (30%), indicating an expanding commercial team building market presence.
Mechanism of Action
(α)- and beta (β)-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients
Started Sep 2026
44 enrolled
EpinephrineHypersensitivity, ImmediateAnaphylaxis
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Started May 2026
446 enrolled
Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Started Feb 2026
20 enrolled
Leg Veins
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Started Sep 2025
30 enrolled
Distributive ShockHemodynamic AssessmentCritical Illness
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Started May 2025
238 enrolled
Hypotension During Surgery
Worked on EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.